How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology
E. Martin(Institut de Cancérologie de l'Ouest), Valérie Seegers(Université Paris Cité), Jean-Louis Legoux(Université Paris Cité), Caroline Pétorin(Centre Hospitalier Universitaire de Clermont-Ferrand), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Karine Le Malicot(Inserm), François C. Bocquet(Centre National de la Recherche Scientifique), Côme Lepage(Inserm), Anthony Turpin(Centre National de la Recherche Scientifique), Thomas Aparicio(Université Paris Cité), Olivier Bouché(CHU Dijon Bourgogne), Louis-Marie Dourthe, Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Catherine Guérin‐Charbonnel(Institut de Cancérologie de l'Ouest), Vincent Bourgeois(Canadian Partnership Against Cancer), Laëtitia Dahan
Cited by 1
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k